FDA Grants Rybrevant Approval for HNSCC
The FDA has granted accelerated approval to Rybrevant for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on platinum chemotherapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed